Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions].

As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations.

Deborah Gordon

Thank you. you Year us XXXX thank Quarter Insulet's and Full and Earnings afternoon, for for joining Fourth Good Call. Chief Executive With President me President McMillan, and Hollingshead, and Vice Chief Executive today Officer; and are Financial Officer. Jim Wayde Christensen, Officer, also Commercial portion our with and Q&A is call. the Executive President for Bret our of Chief Vice us

section Both our XXXX and Relations quarter results and our XXXX guidance the of be of full call on the and this replay fourth the press discussing available will release website. year Investor

Before we certain like of inform statements forward-looking from to made may course differ and call we the current would begin, you expectations. could materially by that Insulet this be during

excluding in with margin, adjusted Please performance, We'll such constant for SEC uses period These revenue gross performance, statements. filings believe explanation growth, respect namely which foreign to discuss from adjusted with they adjusted measures our limitations margin, other refer currency statements parties of are performance supplemental investors, and a financial as in non-GAAP to revenue, as what operating our operating of we to is also the interested helpful period. our exchange. assessing measures align measures and our and measures analysts, to EBITDA of cautionary operating detailed the the effect of inherent management

be rates, will a be Additionally, basis unless which otherwise stated, a with revenue all dollar currency and year-over-year basis. reported on growth exception financial changes will year-over-year commentary percentage regarding the constant of on

I'll turn to the that, call Jim. With over

Jim Hollingshead

was of the XXXX. again, our to record quarter once the achieving exceeded for a us. over which QX, another Insulet U.S. thank expectations revenue global team you and afternoon, growth, cap We delivered in growth a strong end strong not year financial global growth. consistently we Good XX% and and joining were past This XX% Deb. Thanks, achieved remarkable of also a our consecutive year, record performance, critical seventh XXXX customer number milestones. U.S. starts total Omnipod and only XX-plus at of percent levels. of our And new drove marked In for we revenue

global platform, the X. Omnipod have now more roughly XXX,XXX XXX,XXX active on We than customers Omnipod customers on including

quickly fact, over the to to This And and XX% well X delivery CE to new the represented as on product adding our continue pediatric that label for for technology X in customers starts. type we the leading U.S. to U.S. of basal-only market was X obvious Mark approval customer transformative release a our company achievement. Omnipod huge is extending in founded and build full the XXX(k) choice Omnipod X, year, submission pod. to be XXXX is insulin is our for during In of the offer make. Omnipod consumers. the QX, X our our throughout the system was automated momentum completing market age down This as proving The include

come. on our proud clinical look also of During accomplishments to that made in our efforts, opportunities be a I of And people recent evidence the we our property including further work protect strengthened and for we've not more improve these yet should mode at achieved come. everything XXXX, detail our of has capabilities speak for to could our lives in I XXXX, confident top notable mission our in I'll advancing with advancements highlights best the few to of achieved year team about culmination representing years during of diabetes. we a real-world publication Omnipod the more is innovation Insulet am throughout And the X. of first minutes. everything in intellectual the

first cloud-based waterproof connectivity their patient With plug as With when a -- a a number data for to or and the delivered of -- their access compatible Omnipod be physician. market uploaded wait only devices offer unmatched Omnipod means an tubeless the full is control to don't if to AID it's to with X, constant longer visits firsts in AID have truly Omnipod system. X need we to data. smartphone system have X, doctors this customers no pod-based

Omnipod Our their calculator are adaptive blood helps smart include other and no glucose trends, algorithm patients AID levels bolus manage and there the that systems has. that X

These end And advantages box customer right the diabetes management. all competitive significantly predict conversions usage high the of users improve at then current are number that continues each our adoption and market and their are growing X personalizes from are trends automatically out expectations. Omnipod MDI learns switching are their as works and Omnipod of specific competitive our of customer's exceeding It simplify and care. segments. forecast the those from drive all pumps. tube customer to

This percentage brings again X Omnipod coming compared tube split and speaks traditional value our XX-XX was the the QX, tube of In MDI switches. to competitive and to to customers more pump XX-XX traditional estimated from an mix due significantly pumps users. MDI to historical

customer quick Omnipod centers. included regarding experience the complaints also are to call We QX we excellence. of taking all helped support support to to been investments thousands DASH Due to to handheld groups. capabilities, Omnipod action have age primarily X levels to coming and product in certain demand had from who returned address investments back increased potters our Omnipod devices. for customers within adopt and These higher-than-expected once back historical Omnipod win our continue X, us has in This of X. our drive Adopters and

care. the charging and urgency cable. personal announced the Class of the in a to our I We device previously for subsequently ensure team's as and executed respect months. With am the customers our FDA in an the corrective request. upon previously DASH focus within coming this to classified these managers sense MDC, to global actions replacements correction, we complete to expect were Omnipod medical diabetes a we of replacement of to with providing proud of due are X the announced Omnipod process correction The controller X with issue port

innovation we our to is and the to XXX% supports feel mother the Omnipod with said, central results the shared everything recent sleep an we life to touching. me success. mind, again. was from our like customer I do. One my designed way speak designed of daily to a power night. Diabetes in and why the with in we me given the through foreground She Omnipod speaks did. background receive " of X and story I the diabetes X X-year-old back. X experience has Omnipod lives. from was Consumer-focused has moved This user the we product the and particularly the feedback

continued is through unwavering we're an expand multiple to growth access to element and awareness, our strong commitment critical and initiatives. Omnipod A doing this

and during our First DASH and makes Omnipod times. especially more broad pharmacy access growing accessible, X the and With Omnipod low coverage, channel. U.S. is affordable and through co-pays to drive is attractive and simpler, challenging Omnipod presence which adoption in helps economic

we By X Omnipod U.S. expand coverage Second, meaningfully DASH, year-end, Omnipod approached commercial ability for with XX% Omnipod at priced of our X. parity coverage resulting in to lives.

daily $XX the and because technology pharmacy glycemic Additionally, cost improved the our vast customers month to than U.S. control similar our is channel, pay offers outcomes, life. even multiple though injections, a majority quality of the through of less

and also benefit Our access physicians and pharmacy annuity payers. business model

true majority large couple consider traditional to their equipment and the tubed or them on channel. transition our insurance phase on lock-in about you notified especially durable share no the plans classic this eliminated we real I years. either our that of pumps of Omnipod and the value in end to DASH. is average, Omnipod want costs have medical upfront compared lengthy help customer out classic the also plans offers Omnipod legacy sold to is every U.S. This when value individuals vast through U.S. customers since periods. our recently payers base every through technology This by product. longer change that We will X Omnipod We to customer that to of year

XXXX be IDE with year our approval. type is to and also study momentum terms another XXXX. protocol clinical people begin and advancing We safety efficacy U.S. plan in up will from enrollment pivotal Insulet that the focus rolling the into weeks. in study There to was largest study finalized X. demonstrate clinical and conducted XXX the across date will the recruit the for recently FDA type X We carrying of sites targeted efforts, XX X-month a diabetes to our to coming be X to with populations This and received diverse Omnipod exciting in of we've underserved and

achieving. Omnipod valuable hypoglycemia. market and us shared The to able glycemic of pivotal observed clinical settings. months. Yesterday, device to into some minimal data These settings data years maximum evidence. X a will reasons data in reinforced up see we our evidence product ATTD, real-world those This customizable people and first than the by at to the and X X the competitors are new also line trials demonstrated is We're benefits in outcomes results least with system they're in of with for Omnipod for and release our of unmatched come. target which leader using how the XX,XXX glucose contribute at range people Omnipod time be the from of why use avenues for gives more opens X kind for the also insights

limited this below in and connected target striking time it real-world shared extremely data and glycemic we includes users strong minimal Omnipod long-term health that by This promising range on bias, a everyone X is care system. time for range sample real is exceeding world. practitioner all recently benefit the to cloud-based With large Our enthusiasm selection the average. who see since is said is the in set and targets

over user will Our X be real-world every Omnipod for is time since cloud connected. powerful incredibly data

improve can this experience. continue patients, personalize and For we overall to means the

means host health able further is to to streamline tie Omnipod data time, this such population-based build intention to X usage physicians, data their well as to of management workflows. enhancements For Over for other our adoption will drive as as a claims we payers. that be

patients population our that market-leading insights that allow we offerings us This Nobody therapy will product diabetes differentiation. on already create and our means build on level patterns, actual usage unprecedented else all constantly will have from evidence which therapy. can data improve to in includes into

pod, that global market AID winning digital to basal-only commitment we in While diabetes Today, and we future and our pipeline offerings market innovation. innovation type strong are to requires a data thrilled Omnipod a have with X capabilities. the response the includes X,

Today, and estimated win to in deliver result, a an new in X are to our XX% XX% with in the model And a as form customer experience. addition We starts. X. market-leading U.S. type access helping us individuals our population represented type of factor X type unique QX,

product unique position this Omnipod on XXXX with basal-only market in the become our We X patients addressable our the doubling to clear will This X U.S. with total a us users offer for experience our million experience. will expand early to be pod market in build a new entry provide the total as with Omnipod our their We leading as people We competitive help basal-only X insulin of treatment well U.S. approximately into for this TAM. expect comfortable planned believe needs innovation as estimate commercialization type our and market pod. market the and progress. addressable pathway will is alone, adopt on-body the the

of making are We on technology, well. integrate integration market our systems, future leading strengthen iOS offer the progress AID GX will best proposition. our to CGM to X headway DexCom's of today development also value Libre and with generations very to Omnipod in including efforts our system and continue and continue the We great choice, our Abbott's work

leading to us continue unique is our intellectual technologies, deliver To for priority a property. key and our

applications. few improved number patent loop Bigfoot approximately both a many have acquired it has user last Big Food more technology, the Over AID and developed pump years, a innovations. significantly our of portfolio smartphone patents And areas record as patent strong secure patent we and Biomedical, than such organically communications years. over this patent experience patent large XXX including and covering of and closed library control, acquisition. expanded global We year, filings portfolio doubled past and in an through the We

add significant overall strength acquisition these patent of to Our portfolio. intellectual property assets our

to covered grow leading we build other's earlier certain we fourth products current with products. does products positions not moat companies' our a continue exclusions, well into the patents to a and efforts, cloning replaces certainty at the and have duration. each Through provides well quarter, entered years applies agreement to The in over next our other around commercialized our not the and as agreement With pipeline. agreement's products each for this platform as permit innovative X and created broad an both to Additionally, deep one existing agreement more IP expanding us new Medtronic technologies. upon certain assert mutual these and diabetes incredibly that innovation

operations. double-digit the to on Moving of with We impact our growth, had of solid ongoing even year international revenue a AID competition.

to begin the offset beginning the the Omnipod of end in U.K. of XXXX to in year, and expect launch midyear staged headwinds with this of our X We international towards rollout. the marking those Germany in

We broadly launch more plan XXXX. to Omnipod internationally X during

continue global trajectory to and serve support long-term as competitive another manufacturing capabilities Lastly, growth our our moat.

continue conditions macro While global to strong and demand customer challenging, remain Omnipod X. our the we support for base growing

product Our operations highest ahead to of providing customers. demand. secure remain forecasted team quality uninterrupted tirelessly products all and the We to has components build worked our supply global committed and our to

achievements. terrific a to a marked of financial remarkable operational performance strong year end quarter and fourth the closing, In

strengthening remains Insulet in to long-term trajectory. growth executing and the ahead, exciting many mission the entire team and so our committed have our We years opportunities

to turn will the I now call Wayde. over

Wayde McMillan

exciting XXXX of guidance We was our while an XX%. again mission. revenue strong Omnipod the launch of driven delivered fishing high In fourth U.S. Omnipod we range, the results total Thanks, exception. year financial by with above no X growth growth, generated of end the Jim. XX% and advancing QX, was once quarter our

On X basis Omnipod U.S. basis, XX%, a for continues growth a annuity-based contribution DASH for our currency customer and growing record growth X XXX pharmacy year. model and be revenue exceeding revenue, total Omnipod Revenue was pods. to our a foreign volume. of starts by Omnipod Omnipod QX cumulative headwind to driven compared with reported premium includes was range. new an guidance the and last This increasing from point U.S.

starter from was new and where pharmacies. getting some estimated from benefited Omnipod primarily simultaneously first create again well as skipping result Omnipod existing the quarter conversions was DASH benefit in included benefit $XX a we Omnipod, customers refills This primarily future both an driven order some from associated years to Omnipod comparison Classic volume initial X the in dynamic. by and Growth customers This net will as volume XXXX. expect kits million Omnipod partially their conversions volume some by including with of X we offset customers a X refill This customers most retail to tougher X switch as stocking as this in in of benefit Omnipod a ramp.

all of of customer DASH in and new Omnipod as starts is customer were to the our new as an through total the channel DASH. This majority transition Omnipod X QX, is U.S. Omnipod combined milestone XXX% our X During and majority starts. -- pharmacy Omnipod coverage important pharmacy is the is

result, channel As our XX% volume QX, DASH International guidance by quarter. U.S. in fourth increased to approximately total Omnipod revenue a pharmacy above the in driven increased our our volume XX% Omnipod adoption. of range

guide. which headwind a over points currency On a foreign reported XX-point year, X basis, prior versus the was favorable our was approximately

by As was unfavorable a reminder, an impacted reduction comparison. our creating easier an year the million revenue in prior $X channel inventory QX of

higher remain consistent utilization and attrition global with estimated utilization trends prior QX. our QX, in During years with

approximately volume medical range. guidance we points been U.S. trends utilization Delivery fourth foreign our margin the slightly ramp. a $XX basis of the net of device above including Cost the declined the higher impact in charge highest representing utilization Omnipod the approximate revenue or year. with was benefit of XX.X%, XX-point XXX Historically, our has better a million an XX and revenue currency with estimated Gross in X associated of points. XX% initial Note, included Drug decrease, approximately favorable historic than voluntary QX quarter basis correction.

with million the was comprised a to DASH costs MDC, Omnipod offset previously charge partially $X revised our $XX to estimated million due benefit X related associated a MDC. by This of Omnipod net announced

basis with Excluding was charge, adjusted MDC XX.X%, in decrease XXX representing margin expectations. gross QX net the point a line our

our Our operations lower This including and delivery mix growing contributed ramping revenue associated costs mix Omnipod. margin. offset of drug and volume of the positively to higher channel unfavorable in U.S. as premium charge the a than more X from by Omnipod the classic U.S. with manufacturing phaseout gross the well due expected pharmacy associated of as was to

support Both legal the net $X pressures and year-over-year correction respectively. a operating device and higher and Adjusted and performance increase related settlement million adjusted were QX were in invest expectations adjustment. medical our Operating expenses voluntary continued exclude further sales above QX metrics our as EBITDA a in margin XX.X%, to were impacted and XX.X% last charge higher than were business. we year gross benefit margin and an of to Both expenses. operating by in

Turning to We of contribution and DASH and the markets total Omnipod throughout our reported full gross year results. our ongoing for global XXXX, benefit in from demand XXX On growth achieved year revenue unfavorable foreign prior XX%, In of model. of company XX.X%, a the over basis Omnipod revenue adjusted expectations. X our margin basis, down total and annuity-based reflects XX% was we of incredible which Omnipod points. XXX the with delivered growth business basis currency by points line

basis margin points. were our due than gross XX.X%, basis margin our and by and increase down outperformance. was were down operating Adjusted XXX XXX adjusted operating pressures EBITDA to an in higher X.X%, margin Both metrics expectations year-over-year expenses impacted slightly and revenue points. was

and cash the with million liquidity. $XXX We in Turning to cash. ended year

$XXX business. continue investing our strengthened QX, million. remain during financial increasing a addition, by credit We under our position position we our in available solid In agreement in further borrowings our to to

Now outlook. our turning XXXX to

XX%. full XX% to growth For total and Omnipod expect XX% year, revenue of of company growth to the XX% we total revenue

the business as model. of For XX%, DASH Omnipod and U.S. benefits our the adoption XX% as Omnipod by and from pay-as-you-go growth well Omnipod starts, customer Omnipod, X driven coming new continued both conversions strong adoption from of more of of weighted we expect of to of August Omnipod product U.S. revenue expect in tougher of first the our We the X from XXXX. be comparison market year, the given release in the the half year, to to half currently the second revenue a cadence resulting the growth in full another

includes the XXXX. of This in related the of pace second accelerated benefit half customer conversions volume the from

of annuity competitive driven XX%. is For international Omnipod given international X partially On approximately to points. headwinds. ongoing in X% model, expecting foreign basis, estimate Omnipod, introduce not growth AID to exchange X Omnipod XXX later growth this we of offset DASH by currency are we revenue adoption, mainly expect our favorable Growth We basis contribution our impact reported we're Omnipod a for by excited in first to our we international markets -- XXXX. markets while to a material a year,

for we Lastly, what a we XXXX, in decline expect drug delivery XX% representing experienced decline $X a to in XXXX. of to similar XX%,

Turning margin. gross XXXX to

We XX% expect range high a gross with of the at consistent margin XX%, XXXX to end.

offset We favorable by channel to inflation volume expected ramp and mix product manufacturing favorable more be increasing volume. benefit line from increasing geographical U.S. X U.S. costs with our These Omnipod and of associated impact expect pharmacy tailwinds higher in than the mix. are the a sales due to

stated, to factors many of previously our we into we impact these results expect XXXX. As

timing costs This with performance, volume, Omnipod DASH of by improvement corrections. will associated gross improving driven additional year the be year be half high the increasing to and lower end closer to of and of X be the and near sales Omnipod end the half margin range. the the second expect the We the first in of device range of the medical the to manufacturing

efforts to support the including scaling operating markets launch rise expenses well and innovation X sales our in and phased as clinical to functions. We of our pipeline investments our our due international Omnipod marketing and as efforts expect expanding in

investments year similar to single in remain We to XXXX and half improvement We investments margin half of and over of margins. significant the committed due half this be timing expect levels expect the XXXX in to second and to the improved leverage expansion, first high with operating of margin second digits, bolus the beyond. to gross begin to we in

XXXX expect capacity building our as we For to begin capital leverage investments, level expenditures, lower than to we date. a

revenue Turning to first our guidance. quarter XXXX

XXX estimate to XX% unfavorable On impact XX% an of of foreign points. growth XX% exchange basis, we growth total basis to reported Omnipod total and expect a company We approximately of XX%.

growth XX%. U.S. XX% we to For of Omnipod, expect

We record expect including customer our adoption of the the pharmacy starts consistent Omnipod our the to be core the X, U.S. channel new growth annuity model. and as ongoing benefits drivers as well of of

expect timing. Omnipod ongoing AID headwinds we to unfavorable growth estimate a international an estimated by impact points. competitive foreign driven of reported order by partially and exchange basis, of For XXX Omnipod, DASH X% X%, adoption, approximately On we and offset basis

drug year the business. QX shareholders We another execute of XXXX based ahead delivered for delivery be and schedule. our entered solid quarter expect achieved focus we We're momentum in the a and production finish with performance. current to we conclusion, strong fourth financial nominal we In excited about and mission. the in and our incredibly to Finally, year our what revenue strategic come many milestones as clear is global our a and customers further on

operator, that, With for please questions. open the call

Operator

[Operator Our question from Robbie first JP Marcus Morgan. Instructions] from comes

Robbie Marcus

this multiyear is? you adopters taking trend Insulet market new can where the Do is you terms first year-over-year shift basically of patient of I with off really is, I'll It's on or duration, age better off, to much new think you're versus how that switches patients groups, see bit this first you're the question great in overall low all All a congrats the second early the sustainable on the somewhere pharmacy. in half think looks It's XXX% part to work. equation. competitive ask are half. becoming a in share? a right a Well, longer XX% guess new nice my Or like boxes. start market math, it Great. start of my do it's think Maybe By for impressive do towards of and growth. quarter, trend you leader question, converters?

Jim Hollingshead

kits, And a way. There's trend. of it's either obviously, his there -- some starter so here. we about are Omnipod so strong, in here start by But congrats, and we're Wayde and demand, as to X. color Brent quarter, the get hard -- really it's out add we on I'll way to prepared that, your might about Robbie, bullish. strong start want for I'll the on or very things going then it's with remarks, last with really of talked of for the talked we're nature quantitative us think we're gate and in terms Jim. and Thanks bullish

to Omnipod that through revolutionary a great going a for it's Wayde delivering long I'll for will the such to customers such Bret but invite or just persist demand X experience offer -- be is to for and such -- we think results Bret not 'XX, great continue comment. is the way long haul. But

Wayde McMillan

Jim. as it said, with our Omnipod Sure, in. I really this Robbie, reported X a jump platform. here months can is, in Jim start X strong first new in

it's think we so sustainable. And very

Jim type pursuing As know, indication well. you as with GX, be the me, got finalized the and we'll type significant as We'll a pardon X be come X iOS yet. for We to Libre. with X integration an FDA, pipeline we indication innovation -- for X said, so have Type bringing, Omnipod just the trial

just layer time. in going So over innovations a we're to lot more

that us the will So confidence that gives grow. continue to platform

big in the from pharmacy Jim Having DME current our prepared the converting remarks, called that, as a said rate growth customers, moving channel. of our our is into out driver

year. remarks a us we out for that's what tougher will bit next prepared comp a the of that So called in create

incredibly But rest as will the So customers, the convert, from once end be done new of by and convert as done. of DASH they current business because they're of our classic obviously, from them piece just customers XXXX. switches. record we're Omnipod That's be new most and the Omnipod the converters, well. won't competitive sustainable as the MDI customer starts, said, assuming doing Jim X, that

growth edge do long multiyear of the so And cycle. very think we front we're at a

Bret Christensen

Ravi, pile is probably starts. MDI just since on to biggest you indicator asked of new about I'll it. the

promote new waiting said in we Jim mirrored out. in were onboarding XX%, DTC still the but our with we some for maximized, starting record And not and are starts is There think, you'll record was our sustainable. earnest, absolutely things bumps optimizing access But to record MDIs, MDI, overall get quarter. QX. conversions, new is X just also, which some rolling see to then process. really remember, Bill speed were The the we starts. competitive did So Omnipod

my MDI absolutely from So year. sustain can the growth throughout I standpoint, think

Operator

Johnson Our from from next question Jeff comes Baird.

Jeff Johnson

on the Congratulations quarter.

Just wanted I restrictions markets. that the here of warranty to these launch we've us this got year. coming maybe again. guess, periods question, into some level I know Obviously, half of markets in of on some is know the in international we of now on a the stricter ask you X. just second a Jim, Omnipod set couple can there's

true feedback on to mean were of countries just I sure, lot the reimbursement going well to of There's that. was the guys, how I know. interest waiting to worried in of to You're much sooner interest I'm it their here with some But way to commit they was that launching in pursue at I'm some I have her Dr. over going a helpable little for to battling in doctors yesterday, from markets. you Li get data these is point cloud-based ATTD, as a XX regulations, you, through. you're tell of the mean these in to the some XX there

of new start can seen strong patients what fast U.S. out those MDI in of to we've how the competitive win So things markets in international converts, gate the so kind the here relative ramp

Jim Hollingshead

every the heard Jeff. for in we know she to we about as -- into us, such market but of And can changing U.S. session. bit we growth little customers; just as a was we talked it's a tons Omnipod getting here for want great it's we the It's X we Train X actually, fast lives. Omnipod things It's and in And It's we're use. there's such so can. lot Thanks, obviously, just opportunity a the we under -- the We knew because we customers. experience. know from of And benefit interest. pressure feedback to both a a pent great get demand because see to it's people's really simple to

we as first fast So we thing. just as want can, to move

things do to We -- have markets do to and to Germany able both the in we in year And to execute a think we bunch to market specific announced the need a to be And pump we it's there have can set by middle really important the able your for background can. those end more of the obviously, working can large going are put of in those some There bit all market, little get markets. year. when question, be hard thing. get It's obviously interest we're the really the as There's quickly of patients as it, of to that to we They're that. a them. once do into to reach of U.K. and and in quickly a on help want to been little to our continue but Every patients. we're sort people really a of to regulations -- exciting. around that switch different they every has I or it's reasons

general the little that market every I think a a is caveat as different. rule, with

U.S. get U.S., our of channel tube benefit. category as on reimbursement, on rule, can for pharmacy is use As X, as it they X because Omnipod won't trial. different we have people a it over a and pump We're reimbursement switch to the general obviously, pharmacy in be so user Omnipod to can in the the to get in easy an existing free

markets of markets us for European markets, a And standard to under-penetrated. MDI. really still growth a switch stickier. driver little in are the in ability a be lot patient will it the been those those an But bit U.S. And is in European of the That still all huge has

are are as waiting it's to exciting there guide self-injecting us. for who of And a We can. want move people as we bunch said, who get And when market, to for the a bit. come. are And we just as to innovation really little have so Wayde we fast into

somebody And little is to there's got to revenue have our bit ramp. X. how know, about model because an like we on converts things annuity as then cautious We be a Omnipod you

people get they and product builds pods. revenue as the on use So then

we're revenue impact, but fast meet need. we bit there's the underpenetrated how And we to just all in. mindful have guide so markets really the of think we're and to as can important little be we we markets moving of as that across on a

Operator

Our question Jayson Raymond Bedford James. comes from from next

Jayson Bedford

just through a pharmacy, number? that revenue Volume question volume to Maybe is go? simple ceiling the here, Congrats. looking there just that can and growth. Where the the a at

Bret Christensen

channel. This we I'll that you could way other -- that a there because Jayson, All one. X all indication Part business remember, means see the the goes take is but business of channel. Medicare goes through goes CMS, do might from the have our channel. companies pharmacy in it's with Bret. same Omnipod not pharmacy business pharmacy D It's to the be, which Medicaid through

to will still DME we we the So ceiling, ceiling course, and announced fact not and with Medicaid. bit it really outside Omnipod phase do the is contracts But that, the a of channel not our if all with is really, except products we that that channel Omnipod for pharmacy through will of pharmacy little have product in the of volume just go there's of you legacy beyond, there DASH. Medicare, year get look those a all at and X the out past the which, we then end X with a

know much prevents there. than in getting ceiling from be to we'll don't to going we're don't see but So I companies that if us diabetes most XXX%, ever think a get higher

Operator

Wells Biegelsen comes question from next Our Fargo. Larry from

Larry Biegelsen

Congratulations on the strong I here. pod. gears to wanted about a and really quarter shift basal-only ask

saw How you XXX(k). what do to similar approval, to a this quickly X we spot Bret Who the is sorry I'll of I'm all commercialize has You've diabetes on the start what -- the LMR of daily of injections year? who sweet currently doing patients is expecting with product, this for are -- a your you the expect question and type it spot front contribution questions. Omnipod back not think to reasonable? do and injections. customer end comment you ask submitted your questions. for you And daily that kind the started end Larry. next think which or lastly the it We are person X? expect Is is I'm going of start And ideal you expect do sweet year When mid-'XX? just kind with with do Thanks, to

is the they're phobia injections, because upstream going a type And so manage. a are as to X or They have rule, doing basal only a but off trying with it gets a people with have because been they so they've type they to are don't like have or on progression on. what missing Cetin general it needle I lot their lot does mean daily injections they for in because the it putting convenience patient diabetes. daily diabetes people do it. X And

no power stage their of sure their there's to We and customer high make in research power expect think of of we insulin experience, having that lot with or power into ease the into a usage felt casting where there's real a just we really in think need radically transitioning get of daily it, we've can they market. so shows need convenience, simplify with it. we really use, it that there's needles. The in that insulin at done And part that

go importantly, to then which Omnipod from, in the they'll -- and they Almost used use insulin basal-bolus from progresses insulin needs with say, every diabetes Omnipod is And to which customers they Omnipod, type on-body need person experience. get for those their a the they insulin, once-daily go need, who platform, X. intensive X basal needs will is

that transition But gets -- you simplifies so those their offer Bret, people. with would as other genuinely on you experience part X. transition of the be great. Larry's an we're then question, the for might Omnipod upstream ready get And And needs moving them to if could that

Bret Christensen

Yes, absolutely.

part have first on and FDA. around won't we that of the of except is comment said timing question, clearance it your course, Larry, that with the So we

learn. commercial when did happy We There's we want to say fashion, we that's to And launch refine want We did scale so practice. get manufacturing; think this we the we're remember, the speculate approval. build to that. access want won't XXXX a commercialization as we We just just with in we X, with a best with lot we'll model. on in likely Omnipod We've product. limited wil surely to start got we'd

are and So we're today well. payers, those going having with conversations

do call a primary in we launch that model reside expect and with but refining exist the fashion. endocrinology be population care physicians. well. this as -- should tackle now. doctors, of point we'll high-riding You then mostly the where We're the we're figure and limited today, about really which start as primary we we'll product. fills probably with We'll the how out And is in some it's the a exciting, to right plans care, excited practice launch clear need it and We commercial some think going endocrinology family they

Operator

Taylor comes from Jefferies. next Our question from Matt

Matt Taylor

result. good a on Congrats

kind of So I a and have accessed you curious to answer. wanted I'm to your investors this question conceptual ask hear

drugs with new Just drugs. the diabetes of loss all the and

I the you're cure people diabetes on this think for extreme form of most say, argument, in an going use to would and pumps. and market potentially demand your impact "Oh, have

your whether I think Or would that the you say you have actually of of So opportunity what side it to at a who sort investors the curb all? drugs impact can that just market? guess, classes question it's show? about do new whole Does

Jim Hollingshead

that. with start I'll Matt. Thanks,

why we want the with make they their to space. we're The first day of simplify That's to -- care out we to to they -- help want thrilled want in improve lives, outcomes. we We every diabetes innovation people get to want thing their get see diabetes bed the need. sure is we

drug of see innovating we're see data in help. this lot companies, trying to to for a that device companies. so kind people We're to the same companies innovation really whether And of companies, space, happy it's

And a so that's all positive.

see. terms obviously, there's all there been have in these market a In been -- mean, of the it's results and drugs, of the -- new early to days I all lot noise it. around

progression, will people how may progression the with and aimed they know type may the diabetes X or disease. to days at early it's impact they they're impact really, think not of I

have if the is some clinical what the dynamic. think many people X X.X keep of see Western back users, interesting diabetes follows. on But the diabetes, also are there drugs X billion planet you diet of is people I diabetes. were -- look I what the type studies, goes, with at coming type in to them in is, insulin the you those which actually everywhere clinicals Most cases, for an

happy so It's massive And as continue to a them. for people as lot to going and innovations, to a so us than for And platform, growth And we enough to help on see have more be as material medical help. it's global to are don't business. of need. our a with massively think helped there our think underpenetrated innovate get people people is many we new to our we unmet quite a impact There's I it's sustain goal will market. us

Bret Christensen

to and said those. that those the it's from Epiduo it, great not not are the complement insulin of drugs and like is of that soon the basal-only that value know to pod our Jim insulin. We not enough. compete And hear patients -- physicians patients studies those proposition we all on And on Jim said were clinical get we many in time. it a is do out think GLP-Xs, with these now

phobia, people these with complement adherence the improve remove that is in we'll as in product. the basal-only helping And pod type with we again, here think the to for drugs we to diabetes, it. to and are that release X and learn that's already limited goal our spot cases, launch clear so a needle But all the and there's many of

Operator

ask question in of on weeks. Travis from the Bank lately -- next XX patents. your did I side comes few from in Our to Steve the about want been last the movements America. patents

kind of that get years? space over current wanted a pipeline about is also And that XXXX, investments, the the more more of the to margin protecting you it I know heard the beyond I to I leverage litigious of more couple kind portfolio? normal you the to hundred is about of how then expansion. -- leverageable points course kind of in of about ask basis building back X thought you margin you and the -- next are Or about So get think if you expecting can

Jim Hollingshead

then shore up IP our done in It's to done side. certainty. the prepared make as of the are avenues, and margin on but that Wayde the really some concerted made months a ask settlements, for I that, year comments, of to IP on number a all showing we a year. bullish we comment just growing had Medtronic stuff and position we congrats. I'll both. Thanks, sure our actually up Travis, some this we've made little our with And and number your patents the been with of that, bit not and to settlement I'll we thanks working filed And start through IP, said but record we've then we've position We're effort this organically, before position. for that year IP we've including a pay our

offerings of defense, patents. and And as you sort playing both you And end, the terms but it's position position the are are IP, have, then the commercializing you better commercializing more And of better the acquisition creating terms them. right? know, in you of of new IP with also so ideating in

and a find both But patents interesting filed we innovation an and both really rich filed in those. point of view. to great property terms in So of Bigfoot specific Biomedical, very defense. it's we And intellectual patents, granite of of that and it's us had from think patents set on put a offense rich very they position patents and

Wayde McMillan

the of Jim, question. I piece margin could pick the on up

referenced. like cost time higher cost U.S. Omnipod a an margins, to X standpoint, though invest for And macroeconomic with through this and slightly at been for and had make, and to the expansion reducing hit market facility mainly that position, our to and us. we're and heavily And is to gross and this of Jim years, and putting and components the we higher on to committed in in challenges research just investment driven it's would inflection investment pressure just commercial -- that cost continue facility margin invest and and our higher some many a to of choice for decided business continue addition that's pause -- decided of some to so because strategy from Travis, inflationary pressures large cycle to opportunity point felt. even an hit development, that instead we leadership manufacturing We a we businesses of still had you model taking expansion. as couple said, we've we've by here paying our in our that a that have

position we we a leadership you're build sure as strong to right, to that included put up Travis, And now as possible. here. we're remarks, operating in we've and make positioned us prepared till then again in margins best leverage we to continued our got really margins commitment. on want And the and through making to will And that XXXX and investments that a think starting that XXXX. we're given in start gross position

We and the haven't that operations guidance XXXX. to good in U.S. to in we're both a again confident yet we're across in now, and making yet. leverage start put or number our given it with investments We're on just a internationally position the

Operator

X decision or starts how and Jennings 'XX conversions an U.S. Josh the seeing from new you data patient of of Or for accounting for you Omnipod current Wanted Haripaccounting by Type DASH X segment? to XX% from making big starts comes the Cowen. guidance of XX% Thanks and before are The question in very the business. ask next what's clinical the or the or the a -- And just label -- opportunity are to of to XX% for X Our that? type the about you seeing that that slug in patient have to XX% are XX about much. thinking FDA. on we on-label

Bret Christensen

question and on comment I of Josh, Wayde I'll guidance. that can let part first take the

So referenced, percentage we that all new -- to starts. a XX% that's of XX% the

to And all the are so starts new new -- never to type were from on that are are us those new for of that's a brand, pump, either MDI truly for or So those X Omnipod. been and competitive starts coming percent us.

the this for Omnipod high so X algorithm, only And the we've on as lower the been educating today, about half because that's patients numbers are been field a a of get XX%. time It's percentage historically, explaining lot second the spending in to of past X, board. year, physicians staff, Omnipod the high. So but as speaking helping

forward that our portion fantastic. that good offering portfolio and a the the X the talk new writing are where X the look time firing. different. raw field We have devoted not sell with offering has start Omnipod the type field are think really or physicians about value new that to launch just this the been the year a that comfortable type product. so numbers is of with we down. to and now patients Omnipod Omnipod And X in It's percentages can prescriptions We to of But DASH to to that start are

for So a we're opportunity that really it's and really, excited about. fantastic still us underpenetrated is

Operator

next Blair. from from comes William Our Kaczor Margaret question

Margaret Kaczor

you guys from to wanted is and bit retail part have the upgrade a of pharmacy I volume about had maybe it older part a is talk little that generation Omnipod. benefits the just the

XX,XXX of is the And how ones 'XX throughput there? So right in if which we got what pharmacies of terms process take whether where should if you've date, at to XX that and we kind the could even of then those guess, X all you've And U.S. retail the percentage volume numbers in impact of rough us do? or have now individually, upgrades, should guys benefits similarly, are guidance? within all you as I seen a or of not that them

Jim Hollingshead

talk then which, and the prepared the start out know, volume major probably with Sure. Bret, in of remarks. the because are drivers, as about you Margaret, can and expansion we I positioned insights conversion X those Margaret, to the called the best

Omni think, we which to little DASH, existing for market, to over different pump I our who convert upgrades. them classic whether than X, Omnipod confirm cause a conversions, X Just podders, or call is everyone, Omnipod which the

be clear, totals customers. us, into for not or because upgrades, are Those customer conversions annuity an factored new to call And do our it's we new not model.

And people them generations, them. new or from or the move call products whatever we market in older upgrades to don't shipments so call new as others

For where that great us, it's latest just the in customers And at technology. converting progress. making to we're is

in customers remarks, Omnipod to the to wanting and of overwhelmingly existing lot put with a as In of months. frankly, the Jim on X stress couple here system on our fact, some in move of prepared had the success first his

type by and maybe And Omnipod so we them is X reminder, indication XXXX. significant conversions. a until get for the And of of product a for as end Margaret, the customers. But X through that most DASH think, just we'll be X even still after we type

few we'll those a type to be customers so have over and DASH And still quite X. won't converting on X Omnipod

single of the U.S. benefit. So drivers starts, quarters time volume those some had major the the new for in largest driver Obviously, us are is customer and the for customer new start we've record

Bret, So volume with And that's called ramp also, that want a as one? the the quarter stock $X driver we pharmacies. we million pick component of you retail to benefit is you pharmacies, then also start here mentioned, that up do in smaller benefit. retail as out major of the the to

Bret Christensen

Yes, Margaret.

but have pharmacies the so We that because -- in that X? XX to access those with that major the me have a is and job is and building the wholesalers Omnipod distributed And good We've don't we U.S. all do can really is is product to got about talked we to it's done out. the how pharmacies those many of of information wholesalers to answer But don't Omnipod, report get or almost IQVIA pharmacy. X dispense channel pharmacies really important supply the have And I how because really reason them Omnipod all the many XX,XXX retail on what's out obviously from substantial. it's the think important we've

because sends as it's So it's that and is to a as as wholesaler are send about far the -- Omnipod Omnipod pharmacy, how pharmacies pharmacy. far that retail a a there as on not much retail that the will hours physician shelf, to XX XX,XXX really a much when prescription the

the know ability retail In most cases, have up regular Omnipod. the In happening. those is distribute strong. But product cases, that's got when month. pharmacies is they've Omnipod Omnipod customers channel to most how of really picking that reality the stock their those it's And pharmacies they some every do

Operator

from comes question Chris next from Nephron. Our Pasquale

Chris Pasquale

could second -- integration. I provide on was you think should GX really quarter could detail have and something in we when you some been of more then expect sort lack has app you the Is that we 'XX? iOS an Thanks. that the not should in for been but has the it quarter of would you've an launch be great. the a there in successful afterthought next working something Any expect while XX Is in or been, on clarity Hoping now.

Jim Hollingshead

question. your Chris, for start. I’ll

on just our or CGM – working with working anything and and expect We’re Abbott that closely really know, that. and see – really advanced like on notice them available. on don’t important hard, working really become hard we time Dexcom as partners, say ICGM the as integrations extremely across of we that very I’ll those give bullish both completing integration both CGMs and you we’re is we lines we’re space

on as you. We – work really that But we’re we’ll nicely. go that give have really, well. more time app don’t to is, to it lines. iOS, And think, Same progressing we really reporting continues I On answer. not news,

Operator

on This from comes question Kyle. for Canaccord Genuity. Caitlin is next Rose Our from Kyle

upgrades a break pricing of everyone And What's full out to you and the of including that mix 'XX? from volume perspective? impact XXXX, the in can DASH

Wayde McMillan

benefit part in PDM we largely metric no premium coming I'll by you as break out. as That's pharmacy And we of headwind charge. have that have customers the the DME that that we margin the channel. from on Wayde. pharmacy give everybody channel it's we because not new just for as through in that's conversions do gross But the Calin, highlight, the is channel. a remind well the from the driven we

our continue one including ramping And ramp so is the here Omnipod getting the you, benefit break product don't pricing so having been with impacts are volume, that that's will our the X-script it and the larger that's quarters something that, component but cost pharmacy channel. to smaller for in But think we're a X this X we're of be first us gross margins. us, for new we up revenue out couple of The initial -- here, early and in impacts components Omnipod at said we the positive customers it's volume as growth. stages the of and that for metric far significantly positive here that

Operator

Sandler. And from time Piper Matthew It we from for come one question. will have more O'Brien

Matthew O'Brien

me in squeezing for Thanks Great. here.

million. Just couple from -- the in the for -- $XXX you out, up about I question think 'XX from $XX But billion the dollars around the was that there's look know over $XX biloX.X When U.S., Wayde, I you're might for the 'XX in it absolute 'XX Wayde. net you're -- 'XX. an to this $XXX we years when adjustment and saw that U.S. million. to at about in here. about be million stocking I at out last of up million

almost make $XXX you year-over-year So for adjustments you're those million up stocking. again, when those

going out what terms an market, as growth imply to market MDI in place, couple like So know imply does there. the customer you're monster far of that was Because as manufacturing well period? and be well? the there as U.S. on to QX does implied that clearly this revenue you share as conversion acceleration as same the doubling everything thing. as does then infrastructure in what year seems a And perspective, have expanding is, patient far I to do as goes? But And an service patient figure of Omnipod what of that competitive from just there's get QX I'm ASCO trying over almost it a to support adds far what imply or is as side, new

Wayde McMillan

didn't bone of That's a with question there, on to lot I broad the a lot answer. areas Matt. leave a

magnitude the doing be that track that don't were of anything didn't we math have got order honest, to I about in you think and there -- there. that talking stocking were I follow you we the that I

out think to me at, at, we to in hundreds normalization business increases how grow particular, is will don't time, the of in items what to call have or that you're we the we which is getting I let And any the get U.S. try channel. decreases are question From continuing So in and because about. talking the time millions,

-- QX. in just so to we And confirm, nothing had XXXX, for

-- a channel then roll $X so Omnipod X. to normalize U.S. million and quarter, here we $XX for million fourth increase talking as And script third out out in in QX the additional impact when QX, we we've you In started $XX this the had and X% benefit, about in called those, we're

their were aware we orders magnitude certainly And that so the just not but volume customers. to will benefit initial Omnipod so order about. we we is of be as example, say, they being they is script as which is order, this -- pharmacy personal aware X as at, It's everybody customer in of And pods. you of driven for launch dynamic something diabetes of keep a first getting manager to get, the what that also their want September. converting X, by new starter if talking most of And that because is get will well kit, months get their

get would and initial how Omnipod an actually quarter September, see that And they and What customers of a order good second curious did pods. of So kit up we're X. those we their is impact skip percentage first see starter what our use order. is to they their get

QX. see of those the so And as scripts it we was million. you out, getting again, And in approximately benefit $XX well, did X X net for when a people

estimate. that our was so And

out. again, X% normalize If why impact you we're and we're for that's those, calling if it talking you -- a about

that was, of Matt, taking we Bret in call, and share? to United had in in competitive which switches, daily from Jim we're at XX% of There's from question we multiple customers XX% share rates competitive as highlighted injection. growth. we a accelerated market our get means, switches, used record of you Absolutely. about growing number question the earlier If to the past, go the the States, And part are -- above your then, no way

to record Both to You numbers, the on customers, XX% products. of MDs those MDI, coming see XX% therapy new new switches, of competitive number competitive in we now metrics provided our that's here, record switches. of pump record number are coming

share the we call taker continued think us we'll We've a of are to on do leadership a we So the our that be that keep position. drivers some for that of the today about time business think talked things in lot come.

it after with catching leave there, any probably your of clear look up see forward parts I'll and other I can call to the So Matt. if you question. we

Operator

Lichtman we have from Oppenheimer from Steve And Company. question a &

Steve Lichtman

everyone. Congrats,

there? be Can about you'll X? little are you the are it term. on as What And for do kicking form you a what a Omnipod talk X opportunity mentioned that planning plans DTC You that particular once type here near a your off? see down foot that on When take? you putting get will you bit label

Bret Christensen

Omnipod to putting strong it X starting use Omnipod yes, DTC but Bret. we'll been see down, with already. for I start haven't TV digital question. we're we quarter you advertising you'll media, TV. know foot seen it's via and Thanks We've the if don't this social that the Steve, X, start are always with and if to now for

start see create you'll the that pod. DASH we'll So to done that things see how as type X the trial, free goes Have Medicare goes, of type past to in a know X awareness type bit then opportunity we product. with for like And a X. the with opportunity there's But with the little of Basel launch that on with as how focus it see goes. we'll sure far an for

label, you see focus -- course, and Basel Omnipod see anything pod. X. won't pot this be we DTC until with anything I quarter get a will So with for of the won't

Operator

to the conclude remarks. I for This Jim would conference like will today's turn to section. Q&A back Hollingshead closing

Deborah Gordon

about sorry Deb. is Jim, that. This

Just to there your call in in adjusted earnings share that in want per before the earnings was was attention to let you that an close, appendix release, it the just reconciliation. everybody error the I know

adjusted EPS, the non-GAAP been And $X.XX update know issuing just an was have for should be adjustments addition. we'll want that the $X.XX quarter EPS to the that's EPS shortly. not let I to therefore, instead a shown, and reduction of of One everybody in fourth

EPS there Just no as shown. full to note change correct It's for year. the is also, adjusted

ahead. go Jim, Sorry,

Jim Hollingshead

everybody. catch real-time a That's Deb. Thanks,

on hope get to update. everybody the long enough I So that stayed call

our at And everybody, Insulet, So and for today. us world. are shepherding diabetes the is more transforming for These you, deliver landscape, position. competitive improve the the people diabetes and and call. thanks, just really our are Julian, financial we continue performance mission to Omnipod X with lives fulfilling importantly, thanks, and started getting we to And the thank strong around joining times strengthen exciting Deb. global remarkable clearly of

and So thank evening. you a have all, great

Operator

this gentlemen, your conference. day. for today's participation, you have wonderful concludes a Thank and and Ladies

all disconnect. may You

Insulet (PODD) 23 Feb 232022 Q4 Earnings call transcript